5 September 2017
Omega Diagnostics Group PLC
("Omega" or the "Company")
Exercise of Options and Total Voting Rights
Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces that it has allotted 75,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an employee.
Application has been made to the London Stock Exchange for the 75,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 11 September 2017.
After Admission, the total number of Ordinary Shares in issue will be 126,959,060 and the total number of voting rights will therefore be 126,959,060. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Contacts:
Omega Diagnostics Group PLC |
Tel: 01259 763 030 |
Andrew Shepherd, Chief Executive |
|
Kieron Harbinson, Group Finance Director Jag Grewal, Group Sales and Marketing Director |
|
|
|
finnCap Ltd |
Tel: 020 7220 0500 |
Geoff Nash/James Thompson (Corporate Finance) Mia Gardner (Corporate Broking) |
|
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or omega@walbrookpr.com |
Paul McManus |
Mob: 07980 541 893 |
Lianne Cawthorne |
Mob: 07584 391 303 |